Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Filgrastim 13Cyclophosphamide 13Etoposide 12Doxorubicin 11fludarabine phosphate 10Vincristine 10Cyclosporine 10Peripheral Blood Stem Cell Transplantation 9Radiotherapy 8Prednisone 8Vinblastine 6Tacrolimus 6Rituximab 6Methotrexate 6Gemcitabine 6Bleomycin 6tanespimycin 5Vorinostat 5Ipilimumab 5Bortezomib 5temsirolimus 4Sirolimus 4Nivolumab 4Mycophenolic Acid 4Melphalan 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Dacarbazine 4Cytarabine 4CTLA-4 Antigen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hodgkin Disease × iratumumab × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡